Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader
Shanghai Leadingtac Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...
Leadingtac Pharmaceutical
Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development
Shanghai Leadingtac Pharmaceutical Co., Ltd. announced it has received U.S. Food and Drug Administration (FDA)...
Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
Leadingtac Pharmaceutical Co., Ltd. announced the successful completion of its Series B financing round, raising...
Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful...